This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "DESTINY-Breast06 - T-DXd vs. Physician’s Choice of Chemotherapy in HR+/HER2-Low/Ultralow mBC After Endocrine Therapy"

428 views
June 18, 2024
0 Comments
Login to view comments. Click here to Login